Brain Imaging Scores for Predicting Alzheimer's Drug Responsiveness
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
The interaction between amyloid-beta (Aβ) protein deposition and tau protein deposition in the brain, which are key molecules in the pathogenesis of Alzheimer's disease, remains unclear, hindering effective prediction of responsiveness to disease-modifying drugs.
Innovation Solution
A method involving brain imaging to analyze Aβ and tau protein depositions, calculating normalized scores for their interactions in different brain regions, and comparing these scores to thresholds to predict responsiveness to Alzheimer's disease treatments.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If brain imaging is used to analyze amyloid-beta and tau protein depositions, then treatment responsiveness prediction capability is improved, but measurement precision and reliability are insufficient due to unclear protein interaction mechanisms
Solution Approach 1:
The brain is segmented into multiple regions of interest (entorhinal cortex, inferior temporal gyrus, and other cortical regions) to analyze Aβ and tau deposition patterns locally. This segmentation allows precise quantification of protein interactions in specific areas, improving measurement precision while maintaining overall prediction reliability.
Solution Approach 2:
The method calculates normalized scores by transforming raw protein deposition data into standardized parameters. By normalizing the interaction between Aβ and tau depositions across different brain regions, the system achieves both high measurement precision and reliable treatment prediction, resolving the contradiction between these two requirements.
2Reliability
If multiple brain regions are analyzed for protein interactions, then prediction accuracy is improved, but device complexity and computational requirements increase
Solution Approach 1:
The analysis focuses on segmenting the brain into key functional regions (entorhinal cortex, inferior temporal gyrus, and other cortical regions) rather than analyzing the entire brain uniformly. This targeted segmentation reduces computational complexity while maintaining high prediction accuracy through region-specific Aβ-tau interaction analysis.
Solution Approach 2:
The imaging system and analysis methodology are designed to serve multiple functions: quantifying Aβ deposition, quantifying tau deposition, calculating interaction normalized scores, and predicting treatment responsiveness. This multi-functionality reduces overall system complexity by consolidating multiple analytical tasks into a unified platform.
3Manufacturing precision
If normalized scores are calculated for Aβ-tau interactions, then treatment selection precision is improved, but loss of time in analysis processing increases
Solution Approach 1:
The system pre-establishes the methodology for calculating normalized scores and determining treatment eligibility criteria before actual analysis. By preparing the analytical framework and threshold criteria in advance, the actual processing time is reduced while maintaining high precision in therapy selection, as the analysis simply needs to apply pre-defined criteria rather than perform complex real-time calculations.
Data Source
AI summary
The disclosure relates to a system comprising software that predicts responsiveness of healthy subjects or subjects at risk for or suffering from Alzheimer's Disease to certain disease modifying drugs. Embodiments of the disclosure include methods comprising analyzing images of the brain for depositions of amyloid-beta (Aβ) protein and tau protein, and correlating protein deposition levels to drug responsiveness.